753 related articles for article (PubMed ID: 33034095)
1. Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial.
Madariaga MLL; Guthmiller JJ; Schrantz S; Jansen MO; Christensen C; Kumar M; Prochaska M; Wool G; Durkin-Celauro A; Oh WH; Trockman L; Vigneswaran J; Keskey R; Shaw DG; Dugan H; Zheng NY; Cobb M; Utset H; Wang J; Stovicek O; Bethel C; Matushek S; Giurcanu M; Beavis KG; di Sabato D; Meltzer D; Ferguson MK; Kress JP; Shanmugarajah K; Matthews JB; Fung JF; Wilson PC; Alverdy JC; Donington JS
J Intern Med; 2021 Apr; 289(4):559-573. PubMed ID: 33034095
[TBL] [Abstract][Full Text] [Related]
2. Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial.
Park HS; Yin A; Barranta C; Lee JS; Caputo CA; Sachithanandham J; Li M; Yoon S; Sitaras I; Jedlicka A; Eby Y; Ram M; Fernandez RE; Baker OR; Shenoy AG; Mosnaim GS; Fukuta Y; Patel B; Heath SL; Levine AC; Meisenberg BR; Spivak ES; Anjan S; Huaman MA; Blair JE; Currier JS; Paxton JH; Gerber JM; Petrini JR; Broderick PB; Rausch W; Cordisco ME; Hammel J; Greenblatt B; Cluzet VC; Cruser D; Oei K; Abinante M; Hammitt LL; Sutcliffe CG; Forthal DN; Zand MS; Cachay ER; Raval JS; Kassaye SG; Marshall CE; Yarava A; Lane K; McBee NA; Gawad AL; Karlen N; Singh A; Ford DE; Jabs DA; Appel LJ; Shade DM; Lau B; Ehrhardt S; Baksh SN; Shapiro JR; Ou J; Na YB; Knoll MD; Ornelas-Gatdula E; Arroyo-Curras N; Gniadek TJ; Caturegli P; Wu J; Ndahiro N; Betenbaugh MJ; Ziman A; Hanley DF; Casadevall A; Shoham S; Bloch EM; Gebo KA; Tobian AA; Laeyendecker O; Pekosz A; Klein SL; Sullivan DJ
JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38483534
[TBL] [Abstract][Full Text] [Related]
3. Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program.
Wendel S; Kutner JM; Machado R; Fontão-Wendel R; Bub C; Fachini R; Yokoyama A; Candelaria G; Sakashita A; Achkar R; Hamerschlak N; Scuracchio P; Amaral M; Dal Ben M; Araujo D; Soares C; Camargo A; Kallás E; Durigon E; Reis LF; Rizzo LV
Transfusion; 2020 Dec; 60(12):2938-2951. PubMed ID: 32935877
[TBL] [Abstract][Full Text] [Related]
4. Use of Outpatient-Derived COVID-19 Convalescent Plasma in COVID-19 Patients Before Seroconversion.
Wirz OF; Röltgen K; Stevens BA; Pandey S; Sahoo MK; Tolentino L; Verghese M; Nguyen K; Hunter M; Snow TT; Singh AR; Blish CA; Cochran JR; Zehnder JL; Nadeau KC; Pinsky BA; Pham TD; Boyd SD
Front Immunol; 2021; 12():739037. PubMed ID: 34594341
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors.
Benner SE; Patel EU; Laeyendecker O; Pekosz A; Littlefield K; Eby Y; Fernandez RE; Miller J; Kirby CS; Keruly M; Klock E; Baker OR; Schmidt HA; Shrestha R; Burgess I; Bonny TS; Clarke W; Caturegli P; Sullivan D; Shoham S; Quinn TC; Bloch EM; Casadevall A; Tobian AAR; Redd AD
J Infect Dis; 2020 Nov; 222(12):1974-1984. PubMed ID: 32910175
[TBL] [Abstract][Full Text] [Related]
6. ABO blood group and SARS-CoV-2 antibody response in a convalescent donor population.
Bloch EM; Patel EU; Marshall C; Littlefield K; Goel R; Grossman BJ; Winters JL; Shrestha R; Burgess I; Laeyendecker O; Shoham S; Sullivan D; Gehrie EA; Redd AD; Quinn TC; Casadevall A; Pekosz A; Tobian AAR
Vox Sang; 2021 Aug; 116(7):766-773. PubMed ID: 33493365
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation.
Li L; Tong X; Chen H; He R; Lv Q; Yang R; Zhao L; Wang J; Xu H; Liu C; Chen G; Chen S; Li C; Qiao J; Yang J; Wu Y; Liu Z
Transfusion; 2020 Aug; 60(8):1765-1772. PubMed ID: 32627216
[TBL] [Abstract][Full Text] [Related]
8. Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery.
Zimmerli A; Monti M; Fenwick C; Eckerle I; Beigelman-Aubry C; Pellaton C; Jaton K; Dumas D; Stamm GM; Infanti L; Andreu-Ullrich H; Germann D; Mean M; Vollenweider P; Stadelmann R; Prella M; Comte D; Guery B; Gachoud D; Rufer N
Front Immunol; 2021; 12():613502. PubMed ID: 33968017
[TBL] [Abstract][Full Text] [Related]
9. Correlation between Clinical Characteristics and Antibody Levels in COVID-19 Convalescent Plasma Donor Candidates.
Uzun G; Müller R; Althaus K; Becker M; Marsall P; Junker D; Nowak-Harnau S; Schneiderhan-Marra N; Klüter H; Schrezenmeier H; Bugert P; Bakchoul T
Viruses; 2023 Jun; 15(6):. PubMed ID: 37376656
[TBL] [Abstract][Full Text] [Related]
10. Seroconversion and Abundance of IgG Antibodies against S1-RBD of SARS-CoV-2 and Neutralizing Activity in the Chilean Population.
González-Stegmaier R; Cereceda K; Briones JL; Beltran-Pávez C; Oyarzún-Arrau A; Riquelme-Barrios S; Selman C; Yarad F; Mahave M; Caglevic C; Morales R; Aguirre A; Valiente-Echeverría F; Soto-Rifo R; Marsiglia H; Gazitua R; Villarroel-Espindola F
J Immunol Res; 2021; 2021():6680337. PubMed ID: 33644235
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of SARS-CoV-2 antibody responses pre-COVID-19 and post-COVID-19 convalescent plasma transfusion in patients with severe respiratory failure: an observational case-control study.
Klein MN; Wang EW; Zimand P; Beauchamp H; Donis C; Ward MD; Martinez-Hernandez A; Tabatabai A; Baddley JW; Bloch EM; Mullins KE; Fontaine MJ
J Clin Pathol; 2022 Aug; 75(8):564-571. PubMed ID: 33893156
[TBL] [Abstract][Full Text] [Related]
12. Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma.
Thomopoulos TP; Rosati M; Terpos E; Stellas D; Hu X; Karaliota S; Bouchla A; Katagas I; Antoniadou A; Mentis A; Papageorgiou SG; Politou M; Bear J; Donohue D; Kotanidou A; Kalomenidis I; Korompoki E; Burns R; Pagoni M; Grouzi E; Labropoulou S; Stamoulis K; Bamias A; Tsiodras S; Dimopoulos MA; Pavlakis GN; Pappa V; Felber BK
Viruses; 2021 Sep; 13(9):. PubMed ID: 34578426
[TBL] [Abstract][Full Text] [Related]
13. Persistence of SARS-CoV-2 nasopharyngeal swab PCR positivity in COVID-19 convalescent plasma donors.
Ikegami S; Benirschke R; Flanagan T; Tanna N; Klein T; Elue R; Debosz P; Mallek J; Wright G; Guariglia P; Kang J; Gniadek TJ
Transfusion; 2020 Dec; 60(12):2962-2968. PubMed ID: 32840002
[TBL] [Abstract][Full Text] [Related]
14. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels.
Harvala H; Robb ML; Watkins N; Ijaz S; Dicks S; Patel M; Supasa P; Wanwisa D; Liu C; Mongkolsapaya J; Bown A; Bailey D; Vipond R; Grayson N; Temperton N; Gupta S; Ploeg RJ; Bolton J; Fyfe A; Gopal R; Simmonds P; Screaton G; Thompson C; Brooks T; Zambon M; Miflin G; Roberts DJ
Transfus Med; 2021 Jun; 31(3):167-175. PubMed ID: 33333627
[TBL] [Abstract][Full Text] [Related]
15. Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan.
Li C; Yu D; Wu X; Liang H; Zhou Z; Xie Y; Li T; Wu J; Lu F; Feng L; Mao M; Lin L; Guo H; Yue S; Wang F; Peng Y; Hu Y; Wang Z; Yu J; Zhang Y; Lu J; Ning H; Yang H; Fu D; He Y; Zhou D; Du T; Duan K; Dong D; Deng K; Zou X; Zhang Y; Zhou R; Gao Y; Zhang X; Yang X
Nat Commun; 2021 Jul; 12(1):4144. PubMed ID: 34230476
[TBL] [Abstract][Full Text] [Related]
16. Predicting the efficacy of COVID-19 convalescent plasma donor units with the Lumit Dx anti-receptor binding domain assay.
Janaka SK; Clark NM; Evans DT; Mou H; Farzan M; Connor JP
PLoS One; 2021; 16(7):e0253551. PubMed ID: 34310603
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Persistence and Relevant Therapeutic Impact of High-Titer Viral-Neutralizing Antibody in a Convalescent COVID-19 Plasma Super-Donor: A Case Report.
De Rienzo M; Foddai ML; Conti L; Mandoj C; Iaboni S; Saladini I; Castilletti C; Matusali G; Donno DR; Marchioni L; Ianniello S; Corpolongo A; Palange M; Ciliberto G; Piaggio G; De Marco F
Front Immunol; 2021; 12():690322. PubMed ID: 34497602
[TBL] [Abstract][Full Text] [Related]
18. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.
Vandeberg P; Cruz M; Diez JM; Merritt WK; Santos B; Trukawinski S; Wellhouse A; Jose M; Willis T
Transfusion; 2021 Jun; 61(6):1705-1709. PubMed ID: 33715160
[TBL] [Abstract][Full Text] [Related]
19. Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates.
Boonyaratanakornkit J; Morishima C; Selke S; Zamora D; McGuffin S; Shapiro AE; Campbell VL; McClurkan CL; Jing L; Gross R; Liang J; Postnikova E; Mazur S; Lukin VV; Chaudhary A; Das MK; Fink SL; Bryan A; Greninger AL; Jerome KR; Holbrook MR; Gernsheimer TB; Wener MH; Wald A; Koelle DM
J Clin Invest; 2021 Feb; 131(3):. PubMed ID: 33320842
[TBL] [Abstract][Full Text] [Related]
20. Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization.
Salazar E; Kuchipudi SV; Christensen PA; Eagar T; Yi X; Zhao P; Jin Z; Long SW; Olsen RJ; Chen J; Castillo B; Leveque C; Towers D; Lavinder J; Gollihar J; Cardona J; Ippolito G; Nissly R; Bird I; Greenawalt D; Rossi RM; Gontu A; Srinivasan S; Poojary I; Cattadori IM; Hudson PJ; Josleyn NM; Prugar L; Huie K; Herbert A; Bernard DW; Dye JM; Kapur V; Musser JM
J Clin Invest; 2020 Dec; 130(12):6728-6738. PubMed ID: 32910806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
